Start/TMO

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze TMO in workspace
TMONYSE/health care

Thermo Fisher Scientific Inc.

$528.51Up+1.46 (+0.28%)
Research reviewed: 12. Juli 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Thermo Fisher Scientific Inc. operates in Life Sciences Tools and Services within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

시가
524.20
고가
534.73
저가
521.77
시가총액
1964.06억
PER
29.07
52주 최고가
--
배당
0.360%
분기 배당금
--

3-month price context

Das Chart zeigt den jüngsten 3-Monats-Trend, damit Nutzer die kurzfristige Struktur verstehen können, bevor sie den vollen Workspace öffnen.

Investment thesis

Base case
Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services. The base case remains conditional on academic and government weakness staying manageable.
Bull case
Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services. The completed Clario acquisition expands Thermo Fisher's clinical research capabilities and creates cross-selling and productivity opportunities within biopharma services. Continued productivity initiatives can support margin expansion even while end-market recovery remains uneven.
Bear case
Muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand. Slightly declining China revenue and uncertain local funding conditions could delay a broader recovery in Asia-Pacific demand. Debt increased following acquisition activity, raising integration, financing-cost, and capital-allocation risk if expected returns take longer to emerge.
Thesis invalidation
Reassess the thesis if muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand.

Key catalysts

  • Biopharma demand recovery

    Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services.

  • Clario portfolio expansion

    The completed Clario acquisition expands Thermo Fisher's clinical research capabilities and creates cross-selling and productivity opportunities within biopharma services.

  • Productivity execution

    Continued productivity initiatives can support margin expansion even while end-market recovery remains uneven.

Principal risks

  • Academic and government weakness

    Muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand.

  • China market exposure

    Slightly declining China revenue and uncertain local funding conditions could delay a broader recovery in Asia-Pacific demand.

  • Acquisition leverage

    Debt increased following acquisition activity, raising integration, financing-cost, and capital-allocation risk if expected returns take longer to emerge.

Latest earnings research

2026 Q1

For the quarter ended March 28, 2026, Thermo Fisher delivered reported revenue and earnings growth, supported by stronger pharma and biotech demand, acquisitions, foreign exchange, and productivity, while academic, government, diagnostics, and China conditions remained mixed.

Valuation interpretation

  • A premium quality case is supported when recurring consumables and services growth combines with sustained productivity and biopharma recovery.
  • Uneven end markets and acquisition-related leverage warrant a discount if organic growth does not strengthen as integration progresses.

Peer research

DHRABBVJNJ

Recent news

Trefis · 5시간 전

Alamar Hits A High Note On Alzheimer's Buzz

Simply Wall St. · 6일 전

Thermo Fisher (TMO) Wins FBI Approval For Rapid DNA Tool In Crime Investigations

Zacks · 6일 전

Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset?

Zacks · 7일 전

ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base

MedTech Dive · 8일 전

Top 10 medtech deals in the first half of 2026

Zacks · 11일 전

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Data and research sources

Research updated: 12. Juli 2026, 00:00 UTC
3 verified sources
Thermo Fisher Scientific Reports First Quarter 2026 ResultsThermo Fisher Scientific Inc. · earningsVerified

Fetched: 12.7.2026, 0:00:00 UTC

Published: 23.4.2026, 00:00:00

Open original source
Thermo Fisher Scientific Investor RelationsThermo Fisher Scientific Inc. · companyVerified

Fetched: 12.7.2026, 0:00:00 UTC

Open original source
Thermo Fisher Scientific Form 10-Q for the Quarter Ended March 28, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 12.7.2026, 0:00:00 UTC

Open original source

Continue in the research workspace

Keep TMO in context, run a multi-agent analysis, and monitor thesis changes.

Analyze TMO free

Das gesamte Research-System erkunden

Jede Phase erfüllt eine klare Aufgabe und hinterlässt ein prüfbares Ergebnis.

AnalysemethodikMarktberichte lesenAktien erkunden

Continue researching this stock

Marktanalyst

Marktanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Fundamentalanalyst

Fundamentalanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Nachrichtenanalyst

Nachrichtenanalyst fokussiert sich innerhalb von Kernresearch auf die Phase Beobachten und bereitet den Kontext für nachgelagerte Rollen vor.

Risikomanager

Risikomanager fokussiert sich innerhalb von Risiko und Monitoring auf die Phase Überwachen und bereitet den Kontext für nachgelagerte Rollen vor.